ArticleScientific reports2025
Employing diclofenac sodium as a novel therapeutic frontier for Staphylococcus epidermidis infections.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combining Diclofenac and Cannabidiol to Enhance the Antibacterial Capacity of Nonantibiotic Drugs Through Potentiation.International journal of molecular sciences · 2026Article
- Development of New Pyrazolo [3,4-Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of biofilm-forming multidrug-resistant pathogenic bacteria is an alarming public health issue requiring significant research. Drug repurposing is a novel approach to combating bacterial infections that is currently being studied. Here, we explored diclofenac sodium's potential antibacterial and antibiofilm action on Staphylococcus epidermidis bacteria. Diclofenac sodium revealed antibacterial action on S. epidermidis isolates with minimum inhibitory concentrations of 500 to 2000 µg/mL. It also exposed antibiofilm action using the crystal violet assay and scanning electron microscope. Using qRT-PCR, diclofenac sodium has downregulated the expression of the biofilm genes (cna, fnbA, and ica) in 20% of the isolates. An animal model revealed the effect of diclofenac sodium on a systemic infection with S. epidermidis in mice. Diclofenac sodium has improved the liver, spleen, and kidney architecture. Molecular docking was used to explore the possible mechanism for the activity of diclofenac sodium against S. epidermidis, which revealed the high affinity of diclofenac sodium toward S. epidermidis protein and TcaR enzymes. Thus, diclofenac sodium could be a clinical solution for disseminating resistance among S. epidermidis and could be investigated for its combination with different antibiotics in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.